A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.
Advanced Solid Tumor
DRUG: CS1002
safety and tolerability, Number of participants with adverse events, From the day of first dose to 21 days after last dose|area under the curve, (AUC)0-21d, From the time of infusion to 21 days after first dose and forth dose|maximum observed serum concentration (Cmax), From the time of infusion to 21 days after first dose and forth dose
This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.